14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NVS vs BMY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Bristol-Myers Squibb Co. (BMY) is the stronger overall head-to-head candidate over Novartis AG (NVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas BMY carries 57.3/100 (HOLD) at $63.30 (9.5x Forward P/E, 32.4% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs BMY. Trailing 12-month operating profitability (NVS 34.0% vs BMY 32.4%) and valuation multiples (NVS 16.2x vs BMY 9.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment41.2% of Rev ($16.7B)
90D Engineering Disclosures0 Published
BMY Moat ProfileHigh-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $127.4B market capitalization and 32.4% operating margin.
OpEx & R&D Reinvestment38.1% of Rev ($19.1B)
90D Engineering Disclosures0 Published
Investor FAQ NVS vs BMY Key Questions & Quantitative Answers
As of Nov 16, 2026, Bristol-Myers Squibb Co. (BMY) is the stronger overall head-to-head candidate over Novartis AG (NVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas BMY carries 57.3/100 (HOLD) at $63.30 (9.5x Forward P/E, 32.4% operating margin). Technically, NVS sits in a Markup phase (RSI 60.8, UNCLASSIFIED options structure) and BMY sits in a Neutral phase (RSI 55.7, CONSOLIDATION options structure).
BMY leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with BMY at +6.9% YoY revenue growth and -2.8% YoY earnings growth on $50.0B TTM revenue (70.5% gross margin, 32.4% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $50.0B for BMY. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 38.1% of Rev ($19.1B) (0 disclosures) for BMY.
BMY screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas BMY trades at 9.5x Forward P/E, 13.8x Trailing P/E, 17.25x PEG, and 3.3x EV/Revenue (18.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus BMY (44.0% ROE) capital efficiency.
In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, BMY carries 82.3% implied volatility (56th %ile, Balanced (25th–60th %ile)), a 1.29x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.17β · 31% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.